Jazz Pharmaceuticals (JAZZ) Equity Average (2011 - 2026)
Jazz Pharmaceuticals' quarterly Equity Average came in at $4.4 billion in Q1 2026, up 7.04% year-on-year from $4.1 billion in Q1 2025, and up 6.93% quarter-over-quarter from $4.1 billion in Q4 2025.
Jazz Pharmaceuticals has reported Equity Average for 16 years, with the latest figure at $4.4 billion in Q1 2026.
- For the quarter ending Q1 2026, Equity Average rose 7.04% year-over-year to $4.4 billion; the trailing twelve-month figure through Mar 2026 stood at $4.4 billion (up 7.04% YoY), and the FY2025 full-year result was $4.2 billion, up 7.43% from the prior year.
- Equity Average for Q1 2026 stood at $4.4 billion, up from $4.1 billion in the prior quarter.
- The five-year high for Equity Average was $4.4 billion in Q1 2026, with the low at $2.9 billion in Q4 2022.
- Average Equity Average over 5 years is $3.7 billion, with a median of $3.7 billion recorded in 2024.
- Year-over-year, Equity Average slipped 26.32% in 2022 and climbed 23.93% in 2023.
- Tracing JAZZ's Equity Average over 5 years: stood at $2.9 billion in 2022, then rose by 23.93% to $3.6 billion in 2023, then grew by 14.37% to $4.1 billion in 2024, then grew by 0.16% to $4.1 billion in 2025, then advanced by 6.93% to $4.4 billion in 2026.
- The last three Equity Average figures came in at $4.4 billion (Q1 2026), $4.1 billion (Q4 2025), and $3.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn | 4.43 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.43 Bn |
| Dec 31, 2025 | 4.14 Bn |
| Sep 30, 2025 | 3.83 Bn |
| Jun 30, 2025 | 3.94 Bn |
| Mar 31, 2025 | 4.13 Bn |
| Dec 31, 2024 | 4.13 Bn |
| Sep 30, 2024 | 3.97 Bn |
| Jun 30, 2024 | 3.73 Bn |
| Mar 31, 2024 | 3.72 Bn |
| Dec 31, 2023 | 3.61 Bn |
| Sep 30, 2023 | 3.51 Bn |
| Jun 30, 2023 | 3.43 Bn |
| Mar 31, 2023 | 3.21 Bn |
| Dec 31, 2022 | 2.92 Bn |
| Sep 30, 2022 | 2.97 Bn |
| Jun 30, 2022 | 3.40 Bn |
| Mar 31, 2022 | 3.79 Bn |
| Dec 31, 2021 | 3.95 Bn |
| Sep 30, 2021 | 4.03 Bn |
| Jun 30, 2021 | 3.96 Bn |
| Mar 31, 2021 | 3.73 Bn |
| Dec 31, 2020 | 3.52 Bn |
| Sep 30, 2020 | 3.26 Bn |
| Jun 30, 2020 | 2.98 Bn |
| Mar 31, 2020 | 2.96 Bn |
| Dec 31, 2019 | 3.08 Bn |
| Sep 30, 2019 | 3.02 Bn |
| Jun 30, 2019 | 2.86 Bn |
| Mar 31, 2019 | 2.74 Bn |
| Dec 31, 2018 | 2.89 Bn |
| Sep 30, 2018 | 2.95 Bn |
| Jun 30, 2018 | 2.83 Bn |
| Mar 31, 2018 | 2.75 Bn |
| Dec 31, 2017 | 2.59 Bn |
| Sep 30, 2017 | 2.34 Bn |
| Jun 30, 2017 | 2.09 Bn |
| Mar 31, 2017 | 1.93 Bn |
| Dec 31, 2016 | 1.85 Bn |
| Sep 30, 2016 | 1.82 Bn |
| Jun 30, 2016 | 1.76 Bn |
| Mar 31, 2016 | 1.71 Bn |
| Dec 31, 2015 | 1.63 Bn |
| Sep 30, 2015 | 1.51 Bn |
| Jun 30, 2015 | 1.38 Bn |
| Mar 31, 2015 | 1.34 Bn |
| Dec 31, 2014 | 1.36 Bn |
| Sep 30, 2014 | 1.31 Bn |
| Jun 30, 2014 | 1.27 Bn |
| Mar 31, 2014 | 1.28 Bn |
| Dec 31, 2013 | 1.27 Bn |
| Sep 30, 2013 | 1.21 Bn |
| Jun 30, 2013 | 1.17 Bn |
| Mar 31, 2013 | 1.14 Bn |
| Dec 31, 2012 | 1.00 Bn |
| Sep 30, 2012 | 858.77 Mn |
| Jun 30, 2012 | 806.65 Mn |
| Mar 31, 2012 | 487.31 Mn |
| Dec 31, 2011 | 167.06 Mn |
| Sep 30, 2011 | 121.46 Mn |